ANG Lifesciences India Limited
Bombay Stock ExchangeTotal Valuation
ANG Lifesciences India Limited carries a market capitalization of 426.35M, placing it among publicly traded companies globally. Its enterprise value stands at 955.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 426.35M |
| Enterprise Value | 955.37M |
Share Statistics
ANG Lifesciences India Limited currently has 13.06M shares outstanding.
| Shares Outstanding | 13.06M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.26, and the price-to-book ratio stands at 1.85.
| PE Ratio | N/A |
| PS Ratio | 0.26 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 0.46 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 1.03 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 14.13 |
Financial Position
ANG Lifesciences India Limited maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 150.12, indicating elevated leverage, while an interest coverage ratio of -0.71 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.00 |
| Quick Ratio | 0.05 |
| Debt / Equity | 150.12 |
| Debt / EBITDA | -14.12 |
| Interest Coverage | -0.71 |
Financial Efficiency
| Return on Equity (ROE) | -33.38 |
| Return on Assets (ROA) | -5.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.21 |
Taxes
| Income Tax | -19.26M |
| Effective Tax Rate | N/A |
Stock Price Statistics
ANG Lifesciences India Limited's stock has declined approximately -3.28791% over the past 52 weeks. The 50-day moving average sits at 30.69, while the 200-day moving average is 28.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -3.28791% |
| 50-Day Moving Average | 30.69 |
| 200-Day Moving Average | 28.28 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ANG Lifesciences India Limited generated 928.93M in revenue and converted that into -110.85M in net income, yielding earnings per share of -8.47. EBITDA reached -56.21M, while operating income came in at -56.21M.
| Revenue | 928.93M |
| Gross Profit | 323.51M |
| Operating Income | -56.21M |
| Pretax Income | -130.11M |
| Net Income | -110.85M |
| EBITDA | -56.21M |
| EBIT | -56.21M |
| Earnings Per Share (EPS) | -8.47 |
Balance Sheet
ANG Lifesciences India Limited holds 79.80M in cash and equivalents against 793.99M in total debt, resulting in a net debt position of 770.36M. Total book value stands at 130.58M, with working capital of 3.17M providing operational flexibility.
| Cash & Cash Equivalents | 79.80M |
| Total Debt | 793.99M |
| Net Debt | 770.36M |
| Equity (Book Value) | 130.58M |
| Book Value Per Share | 9.97 |
| Working Capital | 3.17M |
Margins
ANG Lifesciences India Limited operates with a gross margin of 34.83, reflecting its pricing power and cost economics. The operating margin of -6.05 and net profit margin of -11.93 provide insight into operational efficiency.
| Gross Margin | 34.83 |
| Operating Margin | -6.05 |
| Pretax Margin | -14.01 |
| Profit Margin | -11.93 |
| EBITDA Margin | -6.05 |
Stock Splits
ANG Lifesciences India Limited's most recent stock split took place on July 13, 2022 with a 4:5 split ratio.
| Last Split Date | 7/13/2022 |
| Split Ratio | 4:5 |
Scores
ANG Lifesciences India Limited posts an Altman Z-Score of 0.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.45 |